Abstract
Patients with high-risk lymphoma have a poor prognosis when treated with standard chemoimmunotherapy. This retrospective study included 23 high-risk lymphoma patients with a median age at diagnosis of 59 (range, 35–68) years. They received 2 cycles of R-COPADM and 2 cycles of CYVE, completed by ASCT for fit patients. With a median follow-up of 46 (range, 3–78) months, three (13%) patients in the cohort died. Nearly half of the patients had an ECOG performance status of 2 or 3. Most patients in the cohort (91%, n = 21) had Ann Arbor stage III-IV disease, and 88% (n = 20) had an IPI of 3 to 5. LDH levels were elevated in 83% (n = 19) of patients. Overall, 30% of patients were identified as having double-expressor lymphoma and 22% as having DHL, while two patients (9%) had THL. The origin of the lymphoma was GC B-cell-like in 15 patients (65%) and ABC-like in 8 patients (35%). Cumulative incidence of relapse at 46 months was 14% (95% CI, 5–37), while overall survival was 87% (95% CI, 64–95) and progression-free survival was 83% (95% CI, 60–93). These results showed the efficacy and an acceptable safety profile of the R-COPADM/CYVE/ASCT regimen in high-risk lymphoma, including patients with DHL.
This is a preview of subscription content, access via your institution
Access options
Change institution
Buy or subscribe
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Learn more
Prices may be subject to local taxes which are calculated during checkout
Data availability
The data sets generated and / or analyzed during the current study are available from the corresponding author on reasonable request.
References
Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. Rituximab for high-risk, mature B-Cell Non-Hodgkin’s Lymphoma in Children. N Engl J Med. 2020;382:2207–19.
Chin CK, Cheah CY. How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 2017;130:867–74.
Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. JCO. 2017;35:2260–7.
See Also3727-Burkitt lymphoma dm R-CODOX-M / R-IVAC overviewR-CODOX-M/R-IVAC Fails to Establish Superior Efficacy Over DA-EPOCH-R in High-Risk Burkitt Lymphoma3725-Burkitt lymphoma R-IVAC (rituximab iFOSFamide etoposide cytarabine)Patient information - Burkitt lymphoma - R-IVAC (rituximab, ifosfamide, etoposide, cytarabine)Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13:175.
Dunleavy K, Gross TG. Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective. Blood 2018;132:369–75.
Shi X, Liu X, Li X, Li Y, Lu D, Sun X, et al. Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and international prognostic index: a multicenter retrospective study. Front Oncol. 2021;11:754964.
Sathyanarayanan V, Oki Y, Issa AK, Ahmed MA, Noorani M, Fanale MA, et al. High risk diffuse large B cell lymphoma: a comparison of aggressive subtypes treated with dose adjusted chemotherapy-the university of Texas MD Anderson eExperience. Blood 2016;128:106–106.
Leppä S, Jørgensen J, Tierens A, Meriranta L, Østlie I, de Nully Brown P, et al. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv. 2020;4:1906–15.
Blay J, Bouhour D, Carrie C, Bouffet E, Brunat-Mentigny M, Philip T, et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin’s lymphoma of patients with no known cause of immunosuppression [see comments]. Blood. 1995;86:2922–9.
Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, et al. Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. haematol [Internet]. 2021 Jul 22 [cited 2022 Jul 20]; Available from: https://haematologica.org/article/view/haematol.2021.278638
McMillan AK, Phillips EH, Kirkwood AA, Barrans S, Burton C, Rule S, et al. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. Ann Oncol. 2020;31:1251–9.
Hartert KT, Wenzl K, Krull JE, Manske M, Sarangi V, Asmann Y, et al. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia. 2021;35:522–33.
Acknowledgements
We thank the team of (Laboratoire d’Anatomie Pathologique, Hopital Saint-Antoine) for their dedication and help with the diagnosis of lymphoma patients.
Author information
Author notes
These authors contributed equally: Tamim Alsuliman, Nicolas Stocker
Authors and Affiliations
Sorbonne University, Paris, France
Tamim Alsuliman,Nicolas Stocker,Elise Corre,Rémy Dulery,Simona Sestili,Laure Ricard,Florent Malard,Mohamad Mohty,Paul Coppo&Zora Marjanovic
Service d’Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France
Tamim Alsuliman,Nicolas Stocker,Elise Corre,Rémy Dulery,Simona Sestili,Laure Ricard,Florent Malard,Mohamad Mohty,Paul Coppo&Zora Marjanovic
INSERM, UMRs 938, Centre de Recherche Saint-Antoine, Paris, France
Tamim Alsuliman,Nicolas Stocker,Elise Corre,Rémy Dulery,Simona Sestili,Laure Ricard,Florent Malard,Mohamad Mohty&Zora Marjanovic
Authors
- Tamim Alsuliman
View author publications
You can also search for this author in PubMedGoogle Scholar
See AlsoIVAC - Macmillan Cancer Support - Nicolas Stocker
View author publications
You can also search for this author in PubMedGoogle Scholar
- Elise Corre
View author publications
You can also search for this author in PubMedGoogle Scholar
- Rémy Dulery
View author publications
You can also search for this author in PubMedGoogle Scholar
- Simona Sestili
View author publications
You can also search for this author in PubMedGoogle Scholar
- Laure Ricard
View author publications
You can also search for this author in PubMedGoogle Scholar
- Florent Malard
View author publications
You can also search for this author in PubMedGoogle Scholar
- Mohamad Mohty
View author publications
You can also search for this author in PubMedGoogle Scholar
- Paul Coppo
View author publications
You can also search for this author in PubMedGoogle Scholar
- Zora Marjanovic
View author publications
You can also search for this author in PubMedGoogle Scholar
Contributions
TA, NS, and ZM designed the study, TA and NS collected the data, and all authors recruited patients. TA, NS, and ZM prepared the manuscript for publication. All authors analyzed the data, reviewed the manuscript, and agreed to its submission for publication.
Corresponding author
Correspondence to Zora Marjanovic.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Alsuliman, T., Stocker, N., Corre, E. et al. Autologous hematopoietic cell transplantation as a part of a sequential multi-phase therapeutic approach (R-COPADM/CYVE/ASCT) as first-line treatment of high-grade B-cell lymphoma: results of a retrospective study with long-term follow-up. Bone Marrow Transplant 58, 437–439 (2023). https://doi.org/10.1038/s41409-022-01902-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-022-01902-4
This article is cited by
-
Antineoplastics
Reactions Weekly (2023)
